Rexahn Pharmaceuticals (RNN) Shares are Down -3.85%

Rexahn Pharmaceuticals (RNN) : During the past 4 weeks, traders have been relatively bearish on Rexahn Pharmaceuticals (RNN), hence the stock is down -18.07% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4% relative to the S&P 500. The 4-week change in the price of the stock is -18.51% and the stock has fallen -3.85% in the past 1 week.

The stock has recorded a 20-day Moving Average of 10.23% and the 50-Day Moving Average is 16.16%.The 200 Day SMA reached 30.44%


Rexahn Pharmaceuticals (NYSEMKT:RNN): The stock opened in the green at $0.22 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.2229 and a low of $0.2092 for the day. The stock did not find buyers even at the lows and closed at $0.21 recording a loss of -2.10%. 1,529,431 shares exchanged hands during the trading day. The stock had closed at $0.21 in the previous days trading.

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *